Protalix posts revenue surge, narrows operating loss but R&D spend and cash burn rise

Protalix BioTherapeutics, Inc. (NYSE: PLX)

Quick facts - latest quarter / six months (from Form 10‑Q ended June 30, 2025)
* Total revenue (six months): $25,771
* Revenues from selling goods (six months): $25,435
* Cost of goods sold (six months): $(14,050) - gross profit = $11,721
* R&D (six months): $(9,467) - up from $(5,848) prior year
* SG&A (six months): $(5,227) - down from $(6,599) prior year
* Operating income (loss) (six months): $(2,973) vs. $(7,283) prior year
* Net income (loss) (six months): $(3,455); three months ended June 30, 2025: $164
* Basic EPS (six months): $(0.04); three months: $0.00
* Cash and cash equivalents: $17,895; Short‑term bank deposits: $15,503 - combined $33,398
* Accounts receivable - Trade: $9,443 (up from $2,909 at 12/31/24)
* Inventories: $21,131 (stable vs. $21,243)
* Total assets: $78,486; Total liabilities: $28,583; Stockholders' equity: $49,903
* Net cash used in operating activities (six months): $(10,291)
* Net cash provided by financing activities (six months): $9,180 (includes $6,812 Sales Agreement proceeds)
* Shares outstanding (Aug 1, 2025): approximately 79,732,115

What's happening inside the company - concise summary
* Commercial execution: sales are being driven by three partners - Pfizer, Chiesi and Fiocruz. For the six months ended June 30, 2025 the company reported sales to Pfizer $12,626, Fiocruz $3,016 and Chiesi $9,793.
* Product mix & timing: Elfabrio (pegunigalsidase alfa) sales to Chiesi ramped sharply in the quarter; Fiocruz (Brazil) purchases fell, creating variability in quarter‑to‑quarter results.
* R&D push: management is increasing R&D for PRX‑115 (PEGylated uricase) and other pipeline programs - R&D expense doubled year‑over‑year and management expects further increases as Phase II work ramps.
* Financing: converted equity under the Sales Agreement generated $6.8M in H1 2025; $15.7M remains available under the amended Sales Agreement. Warrants/options exercises added $2.37M.
* Corporate changes / events: added to Russell 3000/2000 (effective June 27, 2025); CFO transition announced with incoming Sr. VP & CFO effective August 24, 2025.
* Operational risk: company operations are in Israel; management cites geopolitical risk from regional conflict and has measures (multiple storage locations) but the risk remains.

Income statement - positives
* Revenue growth: Total revenue increased to $25,771 (six months) vs. $17,222 prior year - a 49% increase driven primarily by Chiesi and Pfizer orders.
* Improving operating loss: Operating loss narrowed to $(2,973) for six months from $(7,283) - progress toward operating leverage as SG&A declined and revenue rose.
* Recent quarterly profitability: the three months ended June 30, 2025 produced a small net income of $164 (vs. a net loss of $(2,203) a year earlier).
* Strong product partnerships: multi‑year commercial and supply agreements with Chiesi and Pfizer provide near‑term revenue visibility and big milestone upside embedded in partner contracts.

Income statement & cash flow - negatives / risks
* Cash burn from operations: net cash used in operating activities for six months = $(10,291), signaling reliance on financing to cover short‑term gap.
* Rising R&D spend: R&D increased to $(9,467) (six months) from $(5,848) - burns will grow as clinical programs progress (Phase II for PRX‑115 expected H2 2025).
* Working capital pressure: accounts receivable jumped to $9,443 (from $2,909), increasing the cash conversion gap; management recorded a $6.9M increase in receivables that reduced operating cash flow.
* Customer concentration & timing: meaningful revenue concentration with Chiesi and Pfizer and uneven Fiocruz purchases - order timing causes quarter‑to‑quarter volatility.
* Dilution & financing dependence: company raised ~$7.0M via equity under Sales Agreement in H1; continued use of at‑the‑market sales is dilutive and signals reliance on capital markets.
* Tax and FX effects: tax expense of $384 (six months) vs. a prior benefit; financial income (expense) volatility driven by FX and lower interest income on deposits after repayment of convertible notes.
* Geopolitical exposure: Israeli operations create execution risk despite mitigations.

Key near-term items to watch
* PRX‑115 Phase II start and R&D cadence - will drive R&D spend and future valuation upside if clinical data are positive.
* Chiesi order pattern and commercial uptake of Elfabrio - continued bulk ordering or stabilization will determine top‑line consistency.
* Cash runway and financing moves - management says cash + short‑term deposits are sufficient for at least 12 months; remaining Sales Agreement capacity ~$15.7M.
* Collections & working capital - subsequent events show collections of ~$1.4M from Pfizer and ~$7.8M from Chiesi after quarter end (management note).
* Integration of new CFO and any change in financing strategy or cost structure.

Bottom line: Protalix (NYSE: PLX) shows clear commercial progress with revenue up and an improving operating loss, and the business is transitioning to higher R&D investment as clinical work accelerates. That also increases near‑term cash burn and makes the company dependent on partner order timing and periodic equity financing. Investors should track Chiesi/Pfizer demand trends, R&D spend / clinical milestones, and cash‑collection dynamics closely.